Darryl Aliggayu, MD
Internal Medicine · Albany, NYNPI 1982923116
Payments from drug & device makers
Across 227 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$989
- AstraZeneca$688
- AbbVie$329
- Pfizer$286
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$184
- Exact Sciences$173
- plus $1K from 31 others
What the payments were for
- Food & beverage$4,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 57 | $989 |
| AstraZeneca | 43 | $688 |
| AbbVie(2 entities) | 15 | $329 |
| Pfizer | 17 | $286 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $184 |
| Exact Sciences | 7 | $173 |
| Boehringer Ingelheim | 8 | $160 |
| Sunovion Pharmaceuticals Inc. | 7 | $145 |
| Novo Nordisk | 5 | $111 |
| Daiichi Sankyo Inc. | 6 | $94 |
| Merck | 6 | $84 |
| Novartis | 5 | $81 |
| Orexo US, Inc. | 5 | $74 |
| Johnson & Johnson | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Renalytix AI, Inc. | 3 | $51 |
| Amgen | 3 | $48 |
| Eisai Inc. | 2 | $41 |
| Insightec,inc | 1 | $41 |
| Lilly USA, LLC | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Verona Pharma, Inc. | 1 | $28 |
| Viatris Specialty LLC | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Braeburn Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $21 |
| Gilead | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Indivior Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$109
How this compares
$4,094 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 180 | $215,196 |
| EliquisApixaban | 117 | $147,921 |
| JardianceEmpagliflozin | 95 | $81,129 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $77,798 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 288 | $55,773 |
| TradjentaLinagliptin | 40 | $46,525 |
| LinzessLinaclotide | 33 | $33,822 |
| XareltoRivaroxaban | 25 | $32,185 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 34 | $28,255 |
| TrulicityDulaglutide | 13 | $26,202 |
| MounjaroTirzepatide | 19 | $18,703 |
| JanuviaSitagliptin Phosphate | 23 | $18,694 |
| RybelsusSemaglutide | 18 | $17,004 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $15,662 |
| EntrestoSacubitril/Valsartan | 17 | $15,208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $111 | $235,540211 claims |
| PfizerEliquis | $286 | $147,921117 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto | $160 | $147,139163 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $989 | $101,943116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $36 | $44,90532 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta, Bevespi Aerosphere, Nexium | $688 | $42,74094 claims |
| AbbVieLinzess | $329 | $33,82233 claims |
| Johnson & JohnsonXarelto | $67 | $32,18525 claims |
| MerckJanuvia, Belsomra | $84 | $29,66350 claims |
| Indivior Inc.Suboxone | $17 | $28,25534 claims |
| NovartisEntresto | $81 | $15,20817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Albany
- Scott BeegleAlbany$2.1M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.